Pronounced reduction of postprandial glucagon by lixisenatide: a meta‐analysis of randomized clinical trials
- 18 March 2014
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 16 (9) , 861-868
Abstract
Aim: Glucagon‐like peptide‐1 ( GLP ‐1) receptor agonists improve islet function and delay gastric emptying in patients with type 2 diabetes mellitus ( T2DM ). This meta‐analysis aimed to investigate the effects of the once‐daily prandial GLP ‐1 receptor agonist lixisenatide on postprandial plasma glucose ( PPG ), glucagon and insulin levels. Methods: Six randomized, placebo‐controlled studies of lixisenatide 20 µg once daily were included in this analysis: lixisenatide as monotherapy ( GetGoal ‐Mono), as add‐on to oral antidiabetic drugs ( OADs ; GetGoal ‐M, GetGoal ‐S) or in combination with basal insulin ( GetGoal ‐L, GetGoal ‐Duo‐1 and GetGoal ‐L‐Asia). Change in 2‐h PPG and glucose excursion were evaluated across six studies. Change in 2‐h glucagon and postprandial insulin were evaluated across two studies. A meta‐analysis was performed on least square ( LS ) mean estimates obtained from analysis of covariance ( ANCOVA )‐based linear regression. Results: Lixisenatide significantly reduced 2‐h PPG from baseline ( LS mean difference vs. placebo: −4.9 mmol/l, p < 0.001) and glucose excursion ( LS mean difference vs. placebo: −4.5 mmol/l, p < 0.001). As measured in two studies, lixisenatide also reduced postprandial glucagon ( LS mean difference vs. placebo: −19.0 ng/l, p < 0.001) and insulin ( LS mean difference vs. placebo: −64.8 pmol/l, p < 0.001). There was a stronger correlation between 2‐h postprandial glucagon and 2‐h PPG with lixisenatide than with placebo. Conclusions: Lixisenatide significantly reduced 2‐h PPG and glucose excursion together with a marked reduction in postprandial glucagon and insulin; thus, lixisenatide appears to have biological effects on blood glucose that are independent of increased insulin secretion. These effects may be, in part, attributed to reduced glucagon secretion.Keywords
This publication has 38 references indexed in Scilit:
- Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metforminDiabetes, Obesity and Metabolism, 2013
- Human Monoclonal Antibodies against Glucagon Receptor Improve Glucose Homeostasis by Suppression of Hepatic Glucose Output in Diet-Induced Obese MicePLOS ONE, 2012
- Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)Diabetes, Obesity and Metabolism, 2012
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in MonotherapyDiabetes Care, 2012
- GLP‐1 based therapies: differential effects on fasting and postprandial glucoseDiabetes, Obesity and Metabolism, 2012
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in HumansDiabetes, 2011
- Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor FunctionExperimental Diabetes Research, 2011
- Glucagon Deficiency Reduces Hepatic Glucose Production and Improves Glucose Tolerance In Adult MiceMolecular Endocrinology, 2010
- The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering ActionDiabetes, 2010
- Functional receptors for the insulinotropic hormone glucagon‐like peptide‐I(7–37) on a somatostatin secreting cell lineFEBS Letters, 1991